Recent data from the HOMAGE trial investigating the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure showed that serum procollagen type I C-terminal propeptide is lower in spironolactone-treated patients. This evidence concerns the gene COL1A2 and heart failure.